{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Cell+therapy",
    "query": {
      "intervention": "T-Cell therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2397,
    "total_pages": 240,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Cell+therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T14:32:55.277Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05332054",
      "title": "Long-Term Follow-up Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma, Non-Hodgkin",
        "Relapsed Non-Hodgkin Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Lymphoma",
        "B Cell Lymphoma",
        "B-Cell Non-Hodgkin's Lymphoma",
        "Hematologic Malignancy",
        "Relapsed/Refractory Multiple Myeloma",
        "Relapsed/Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Caribou-sponsored investigational therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Caribou Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2022-03-16",
      "completion_date": "2041-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332054"
    },
    {
      "nct_id": "NCT03391466",
      "title": "Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Axicabtagene Ciloleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Platinum-containing Salvage Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 359,
      "start_date": "2018-01-25",
      "completion_date": "2024-11-25",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 30,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03391466"
    },
    {
      "nct_id": "NCT07464951",
      "title": "CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Anti-CD123 LV redirected T cells (CART123)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib (JAKAVI®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Stephan Grupp MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "0 Years to 29 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-05-14",
      "completion_date": "2030-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07464951"
    },
    {
      "nct_id": "NCT04883645",
      "title": "Neoadjuvant Imiquimod Immunotherapy for Oral Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Oral Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Imiquimod 5% Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 16,
      "start_date": "2022-04-28",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-28",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883645"
    },
    {
      "nct_id": "NCT03388632",
      "title": "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Treatment-Refractory Cancers"
      ],
      "interventions": [
        {
          "name": "rhIL-15",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECHO",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT Scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-02-05",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388632"
    },
    {
      "nct_id": "NCT00176826",
      "title": "T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hemophagocytic Lymphohistiocytosis",
        "X-Linked Lymphoproliferative Disorders",
        "Chediak-Higashi Syndrome",
        "Griscelli Syndrome",
        "Immunologic Diseases",
        "Langerhans-Cell Histiocytosis",
        "Hematologic Diseases"
      ],
      "interventions": [
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Myeloablative conditioning regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "Up to 55 Years"
      },
      "enrollment_count": 22,
      "start_date": "2000-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176826"
    },
    {
      "nct_id": "NCT00160355",
      "title": "Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wiskott-Aldrich Syndrome"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Miltenyi CliniMACS selection system",
          "type": "DEVICE"
        },
        {
          "name": "Fludarabine, Melphalan, Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "Up to 18 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2005-05",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00160355"
    },
    {
      "nct_id": "NCT05461378",
      "title": "PREP (Pre-Exposure Prophylaxis) of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immuno-Deficiency",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Evusheld",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ghady Haidar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2022-07-26",
      "completion_date": "2024-01-29",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05461378"
    },
    {
      "nct_id": "NCT00621452",
      "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Chronic Lymphocytic Leukemia",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Splenic Marginal Zone Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "gene rearrangement analysis",
          "type": "GENETIC"
        },
        {
          "name": "lymph node biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "genetically engineered lymphocyte therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bone marrow aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "enzyme-linked immunosorbent assay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2007-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-08-06",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00621452"
    },
    {
      "nct_id": "NCT04927884",
      "title": "A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PD-L1 t-haNK",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sacituzumab Govitecan-Hziy",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2021-09-08",
      "completion_date": "2022-12-12",
      "has_results": true,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-09-04T14:32:55.277Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927884"
    }
  ]
}